Two series of benzimidazole derivatives were sythesised. The first one was based on 5,6-dinitrobenzimidazole, the second one comprises 2-thioalkyl-and thioaryl-substituted modified benzimidazoles. Antibacterial and antiprotozoal activity of the newly obtained compounds was studied. Some thioalkyl derivatives showed remarkable activity against nosocomial strains of Stenotrophomonas malthophilia, and an activity comparable to that of metronidazole against Gram-positive and Gram-negative bacteria. Of the tested compounds, 5,6-dichloro-2-(4-nitrobenzylthio)-benzimidazole showed the most distinct antiprotozoal activity.
potent decouplers of oxidative phosphorylation in mitochondria. They are also inhibitors of photosynthesis, and some exhibit appreciable herbicidal activity [8] . Most recently, antiprotozoal activity of substituted 2-trifluorobenzimidazoles has been reported [9] , consistent with several earlier studies on the anti-giardial activity of various benzimidazole derivatives [10, 11] . However, the general antimicrobial activity of benzimidazole derivatives has not been extensively investigated. The earliest report of their antibacterial activity appeared in 1964 [12] , and more recently we have found two groups of substituted benzimidazoles, namely the 5,6-dinitro and 2-trifluoromethyl derivatives, to be promising candidates for antimicrobial drugs [13] . In this paper we present new data on the antimicrobial and antiprotozoal activities of 5,6-dinitro and 2-dialkylaminosubstituted benzimidazoles.
MATERIALS AND METHODS

General methods.
All chemicals and solvents were purchased from Sigma-Aldrich. Melting points (uncorr.) were measured in open capillary tubes on a Gallenkamp-5 melting point apparatus. Ultraviolet absorption spectra were recorded in a Kontron Uvikon 940 spectrophotometer. 1 Antimicrobial activity was tested by the disc-diffusion method under standard conditions using Mueller-Hinton agar medium as described by NCCLS [14] . Sterile filter paper discs (9 mm diameter, Whatman No. 3 chromatography paper) were soaked in test compound solutions prepared in EtOH/Me 2 SO mixture (1:1, v/v) and finally contained 400 mg of the compound per disc. The results were read following 18-20 h incubation at 35°C. MIC -the minimum inhibitory concentration -was performed by the agar dilution method according to guidelines established by the NCCLS [15]. MIC was described as the lowest concentration of the drug that visibly inhibited growth. A single colony or faint haze was regarded as no growth. MICs were interpreted after 18 and 42 h of incubation at 35°C. Concentrations of agents in MullerHinton II Agar medium (Becton Dickinson) ranged from 12.5 to 400 mg´cm -3 . Agar plates were inoculated using a replicator with 2 ml volumes. The final inoculum of bacteria was 10 -4 CFU´cm -3 . Solutions of the agents tested were prepared in 0.125 M HCl, for compounds 4d, 4f and 4n, and in a 0.125 M HCl/MeOH mixture (1:0.6, v/v) for compound 4e. Protozoan parasite isolates, culture and drug susceptibility assays. Giardia duodenalis, Trichomonas vaginalis and Entamoeba histolytica were grown in TYI-S-33 which was supplemented with bile for Giardia [16] . Parasites were subcultured three times a week ex-cept for Entamoeba which was subcultured twice a week [16] . T. vaginalis strain BRIS/ 92/STDL/F1623 and the metronidazole resistant line derived from it BRIS/92/STDL/ F1623-M1 (F1623-M1), E. histolytica strain HTH-56:MUTM (MUTM) and G. duodenalis strains BRIS/83/HEPU/ 106 (referred to as 106), the metronidazole-resistant line BRIS/83/HEPU/106-2ID 10 derived from 106 (106-2ID 10 ), WB1B, the metronidazole-resistant line WB-M3 and the albendazole resistant line WB-M3-Alb (WB/Alb) are described in [16] . Drug susceptibility assays were detailed previously [16] . 
S-alkylated and -arylalkylated derivatives of C-substituted benzimidazoles (4a-m). 2-(Dimethylaminoeth-1-ylthio)
benzimidazole (4a): 0.6 g (4 mmol) of 2-thiobenzimidazole was dissolved in acetonitrile (20 ml) containing 2 ml (14 mmol) DBU followed by the addition of 0.72 g (5 mmol) of 2-dimethylaminoethylchloride hydrochloride. The solution was stirred overnight at room temperature and the solvent evaporated. Water (5 ml) was added to the residue and the mixture was brought to pH 7 with CH 3 COOH. 4,6-Dichloro-2-thiobenzimidazole (6): 1.168 g (6.6 mmol) of 1,3-dichloro-4,5-diaminobenzene (5) was dissolved in a mixture of EtOH (13 ml) and water (2 ml), followed by the addition of 0.8 ml (13.2 mmol) of carbon disulfide and 1.48 g (26.4 mmol) of KOH. The solution was stirred under reflux for 2 h, decolorized with charcoal and brought to pH 5 with acetic acid. The yellowish chromatographic pure precipitate was removed by filtration. Yield 0.9 g (62%). A small amount for analysis was crystallized from water: (m.p. > 300°C 
RESULTS AND DISCUSSION
Chemical synthesis
In order to expand the group of benzimidazole derivatives, we synthesised several new benzimidazole ring-containing compounds. In addition to the earlier reported 5,6-dinitro-and 4,6-dinitrobenzimidazoles, their nucleosides and 5,6-dinitro-2-trifluoromethylbenzimidazole [17, 18] , we have undertaken the synthesis of a series of 1-substituted 5,6-dinitrobenzimidazoles (2a-f) by alkylation of 5,6-dinitrobenzimidazole (1) with appropriate halogenoalkylamine in acetonitrile using 1,8-diazabicyclo [5, 4 ,0]undec-7-en (DBU) as a base. Additionally, 5,6-dinitro-1-(2,3-dihydroxyprop-1-yl)benzimidazole (2g) was obtained in the reaction of 1 with glycitole under the same reaction conditions (Scheme 1). The choice of 1-substituents was motivated by their presence in numerous drugs showing a variety of antimicrobial, psychostimulant and other activities.
The second series were sulfur-substituted derivatives of a modified benzimidazole nucleus. The methyl-, chlorine-and carboxy-substituted derivatives of 2-thiobenzimidazoles (3a-m) were S-alkylated with halogenoalkylamines, allyl chloride, or benzyl chloride and its p-nitro and 3,4-dichlorosubstituted derivatives to provide the corresponding derivatives (4a-o). The substrates 3a-m were previously synthesised by the reaction of carbon disulfide with the corresponding phenylenediamine [6] . The novel 4,6-dichloro-2-thiobenzimidazole (6) was similarly prepared by treating 1,3-dichloro-4,5-diaminobenzene (5) with carbon disulfide (Scheme 2). The resulting derivatives were purified by crystallization or flash column chromatography. In a few cases it was necessary to transform the products into their respective hydrochlorides to obtain a crystalline material. Of the N-and S-substituted derivatives shown in Schemes 1 and 2, only 3c has been previously mentioned in the patent literature [19] .
Antibacterial activity
The antibacterial activity of the benzimidazole derivatives was first tested by the agar disc-diffusion method against Gram-positive and Gram-negative bacteria. The results of these studies are summarized in Table 1 . The compounds not shown in the table had no antibacterial activity. The new benzimidazole derivatives reported here, particulary 4d-4n, are approximately as active as metronidazole used as a control substance. In the case of enterobacteria, such as E. coli and P. vulgaris, the bezimidazoles 4d-4n exhibited moderate activity, whereas metronidazole was inactive.
On the other hand, metronidazole was more active against bacilli then 2g and 4a-f and 4n.
More attention was devoted to the investigation of antibacterial activity against Stenotrophomonas maltophilia strains. S. maltophilia (previously called Pseudomonas maltophilia and Xanthomonas maltophilia) is an increasingly recognized nosocomial pathogen, particularily for immunocompromised patients. Risk factors for S. maltophilia are colonization and infection due to mechanical ventilation, previous exposure to broad spectrum antibiotics, fungal infections, catheterization, prolonged hospitalization and the use of equipment contacting with the respiratory tract, such as nebulizers. S. maltophilia is found in a wide variety of ageratic, soil, and rhizosphere environments and on various contaminated materials and fomites, including faucets, showers, ice-making machines etc. Several of these have been implicated as sources of nosocomial infections with S. maltophilia. With the exception of trimetoprim-sulfamethoxazole (Biseptol, Cotrimorazole), many post-therapy isolates of S. maltophilia quickly become resistant to antimicrobial agents [20] . The tests presented here (Table 2) show that only compounds 4d, 4e, 4f and 4n, which are inactive against standard and nosocomial strains of B. cepacia and P. aeruginosa, were active against nosocomial strains of S. maltophilia. Compounds 4f and 4n displayed antibacterial activity also Vol. 49 Nitro-and halogeno-substituted benzimidazole derivatives 191
Scheme 1
against the standard strain of S. maltophilia NCTC 13637 (MIC 400 and 200 mg/ml, respectively). Derivatives 4d and 4e -inactive against standard strains of Pseudomonas family -are active against all of nosocomial strains of S. maltophilia (MIC 50-400 mg/ml) tested here. In contrast, compounds 4f and 4n moderately active against standard strains, were inactive against 49 and 16 nosocomial strains.
The results obtained indicate that the compounds studied here or their possible structural analogues could be potential chemotherapeutics in the case of S. maltophilia infection. It is noteworthy that the nosocomial S. maltophilia strains examined here were resistant to b-lactam antibiotics, including penems, azeotronams and cephalosporins of the 3rd generation and showed considerable resistance to aminoglycosides and quinolones.
Scheme 2
Anti-protozoal activity Drugs (0.1 M) dissolved in dimethyl formamide (DMF) were used in microtitre plate susceptibility assays as previously described [16] . In a few cases (2c, 4f, 4c, 4n ) the compounds required mild heat for dissolution. 4e was soluble at 10 mM and 4h crystallized in the assays at > 100 mM. MIC values for 1, 2a-2g and 4a-o were estimated as previously described and only compounds with MICs < 100 mM in any assay are presented in Table 2 . The MIC values for metronidazole (Mz) and albendazole (Alb) are also presented. While neither of the compounds was uniformly as effective as metronidazole, or as effective as albendazole against Giardia, several compounds had MIC values which should encourage further development as lead compounds in a search for new anti-anaerobic Vol. 49 Nitro-and halogeno-substituted benzimidazole derivatives protozoal clinical agents. Compounds 2a, 2b, 2c, and to a lesser extent 2e, were the most effective against T. vaginalis. These 5,6-dinitro-1-(aminoethyl)benzimidazoles may act via reduction of the nitro group via ferredoxin in the same way metronidazole acts, but not as inhibitors of tubulin polymerization as albendazole does, since the metronidazole-resistant line F1623-M1 was not susceptible to these compounds. This is what is expected of drugs with a similar mechanism of action to metronidazole.
The compound 4h and to a lesser extent 4o were the most effective against Giardia and Entamoeba. While 5,6-dichloro and 4,6-dichloro benzimidazoles carry a nitrobenzyl group, the mechanism of action may not be via the nitro group, since the metronidazole-resistant Giardia lines and the parent isolates were similarly susceptible. In addition, the MIC of 4h against Entamoeba was the same as that of metronidazole. Compound 4l which also carries the nitrobenzyl group but is a 5-carboxybenzimidazole, rather than a dichloro-benzimidazole, was ineffective in all assays suggesting that the nitrobenzyl group was not the all-important functional moiety in 4h and 4o. Since benzimidazole compounds have not previously been shown to be effective against Entamoeba and in our hands albendazole is ineffective against Trichomonas (Table 3) , our results, particularly those for 4h, are worth pursuing in the search for new effective anti-protozoal drugs.
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